Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ark Bio Reports Positive Results from Phase II Trial of Novel RSV Treatment

publication date: Nov 6, 2019

Ark Biosciences, a Shanghai biotech, reported positive topline results from a Phase II proof-of-concept study of Ziresovir (AK0529) in infant patients with respiratory syncytial virus (RSV) infection. The company said it was the first time an antiviral agent has successfully treated infants hospitalized with the infection. In its Phase II study, Ziresovir demonstrated a dose-dependent clinical efficacy, reducing patients’ signs and symptom scores along with their viral loads. Patients did not experience any safety issues. Ark plans to advance the antiviral into Phase III registration trials. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here